News
OBI Pharma Announces Discontinuation of the Phase 1/2 Study of its Antibody- OBI 888 to focus on other priority Cancer programs
OBI Pharma, a Taiwan biopharma company (TPEx: 4174), today announced discontinuation of the Phase 1/2 Study* for OBI 888, a Globo H antibody, upon completion …
Poster Presentations at the 2022 ASCO Annual Meeting for Adagloxad Simolenin, OBI-999, and OBI-3424
Title: A phase 3, randomized, open-label study of the anti-Globo H vaccine Adagloxad Simolenin/OBI-821 in the adjuvant treatment of high-risk, early-stage, Globo H-positive triple-negative breast …
OBI Pharma Announces Poster Presentations at the 2022 ASCO Annual Meeting for Adagloxad Simolenin, OBI-999, OBI-3424, and Exhibition Booth
Poster Presentations to highlight the ongoing clinical studies targeting Globo H and AKR1C3 OBI Pharma, Inc. (TPEx: 4174), a leader in First-in-Class Cancer therapeutics, today …
Poster Presentations at AACR 2022 Annual Meeting for OBI-3424 and Globo H Science
Title: OBI-3424, an AKR1C3-activated prodrug, exhibits in vivo synergistic anti-tumor effect in combination with pembrolizumab by induction of immunogenic cell death Poster number: 6111 / …
OBI Pharma Announces Poster Presentations at AACR 2022 Annual Meeting for OBI-3424 and Globo H Science
Poster Presentations to highlight the latest research on OBI-3424 (AKR1C3 small molecule pro-drug) and emerging Globo H science. OBI Pharma, Inc. (TPEx: 4174) today announced …